Trials / Unknown
UnknownNCT03800706
A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Single-Arm, Open-Label, Multicenter Clinical Trial. To observe the efficacy and safety of TQB2450 in patients of non-hodgkin lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 | TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks. |
Timeline
- Start date
- 2019-03-25
- Primary completion
- 2021-06-30
- Completion
- 2021-12-31
- First posted
- 2019-01-11
- Last updated
- 2020-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03800706. Inclusion in this directory is not an endorsement.